A strategic agreement to accelerate the development of new drugs

The CRG and the drug identification company Chemotargets, a spin-off of IMIM, have joined forces to promote the development of new therapies for different diseases, such as cancer or fibrosis.

Artificial intelligence and computational methods will save a lot of time in drug development. Photo by the National Cancer Institute on Unsplash.

The Centre for Genomic Regulation (CRG) and the biotechnology company Chemotargets have reached a collaboration agreement to facilitate and accelerate the process of searching for therapeutic targets and the subsequent drug development.

This initiative combines, on the one hand, the experience of the CRG in the identification of new therapeutic targets for diseases such as cancer, fibrosis, eye diseases, blood diseases or diseases that cause inflammation; and on the other, the cutting-edge technology, computational methods and data analysis offered by Chemotargets – a spin off of the Hospital del Mar Medical Research Institute (IMIM), another of the PRBB centers.

“Partnering with Chemotargets will be a vital boost to leverage our know-how for the benefit of patients in need”
Luis Serrano, director of the CRG.

The first common project will be focused on the CRG Cellular and Developmental Biology group led by Isabelle Vernos to study therapeutic targets related to infertility and cancer (processes related to cell division, area of expertise of the group).

To learn more about Isabelle Vernos’ group and the research they carry out, don’t miss the following video made on the occasion of the PRBB’s open week:

Leave a Reply

Your email address will not be published. Required fields are marked *